- Home
- CLDI vs DWTX Comparison
CLDI vs DWTX Comparison
Compare CLDI & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- DWTX
- Stock Information
- Founded
- CLDI 2014
- DWTX 2012
- Country
- CLDI United States
- DWTX United States
- Employees
- CLDI N/A
- DWTX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- DWTX
- Sector
- CLDI Health Care
- DWTX
- Exchange
- CLDI Nasdaq
- DWTX NYSE
- Market Cap
- CLDI 10.2M
- DWTX 9.2M
- IPO Year
- CLDI N/A
- DWTX N/A
- Fundamental
- Price
- CLDI $0.71
- DWTX $4.82
- Analyst Decision
- CLDI
- DWTX Strong Buy
- Analyst Count
- CLDI 0
- DWTX 1
- Target Price
- CLDI N/A
- DWTX $10.00
- AVG Volume (30 Days)
- CLDI 41.3M
- DWTX 28.7K
- Earning Date
- CLDI 08-12-2025
- DWTX 08-14-2025
- Dividend Yield
- CLDI N/A
- DWTX N/A
- EPS Growth
- CLDI N/A
- DWTX N/A
- EPS
- CLDI N/A
- DWTX N/A
- Revenue
- CLDI N/A
- DWTX N/A
- Revenue This Year
- CLDI N/A
- DWTX N/A
- Revenue Next Year
- CLDI N/A
- DWTX N/A
- P/E Ratio
- CLDI N/A
- DWTX N/A
- Revenue Growth
- CLDI N/A
- DWTX N/A
- 52 Week Low
- CLDI $0.20
- DWTX $1.62
- 52 Week High
- CLDI $3.89
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- CLDI 65.65
- DWTX N/A
- Support Level
- CLDI $0.23
- DWTX N/A
- Resistance Level
- CLDI $1.60
- DWTX N/A
- Average True Range (ATR)
- CLDI 0.15
- DWTX 0.00
- MACD
- CLDI 0.07
- DWTX 0.00
- Stochastic Oscillator
- CLDI 36.55
- DWTX 0.00
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.